Argenica Therapeutics Health Care

$0.375 0.005 (1.35%)

High $0.38	Low $0.38	Trades 2	Turnover $1,293	Volume 3,448
30 June 2023 at 10:43am

Register to track AGN and receive email alerts.

Market Cap (19-Sep) $14,130,238 (1,586th)	Close (30-Jun) $0.375 0 (0%)	Volume (30-Jun) 3,448	Shortsold (16-Aug) 1,155 (0.00%) (595th)
52w High $0.79	52w Low $0.105	P/E -	EPS -0.08

	Subject
	AGN AGN Ann: ARG-007 Protects Brain Cells in Moderate TBI Model
	1 (current) 2 3
	AGN AGN Ann: Becoming a substantial holder
	AGN AGN Ann: Becoming a substantial holder
	AGN AGN Ann: Application for quotation of securities - AGN
	AGN AGN Ann: Notification regarding unquoted securities - AGN
	AGN AGN Ann: Cleansing Notice
	AGN AGN Ann: Application for quotation of securities - AGN
	AGN AGN Ann: Release of Restricted Securities From Escrow
	AGN AGN Ann: Proposed issue of securities - AGN
	AGN AGN Ann: Argenica Successfully Completes $4.0m Placement
	AGN AGN Ann: Trading Halt
	AGN AGN Ann: Final Phase1 Clinical Trial Report
	AGN AGN Ann: Quarterly Activities/Appendix 4C Cash Flow Report
	AGN AGN Ann: Latest Preclinical HIE Study Results
	AGN AGN Ann: Significant Non-Dilutive Funding For Preclinical HIE Studies
	AGN AGN Ann: Interim Phase 1 Safety Report Confirms Safety of ARG-007
	AGN AGN Ann: Half Yearly Report and Accounts
	AGN AGN Ann: Non-Dilutive Funding Received to Progress Alzheimers Studies
	AGN AGN Ann: Preclinical Data Shows ARG007 Inhibits a Cause of Alzheimers
	AGN AGN Ann: Investor Presentation
	AGN AGN Ann: Quarterly Activities/Appendix 4C Cash Flow Report
	AGN AGN Ann: Argenica Awarded $1.2m CRC-P Grant for TBI Project
	AGN AGN Ann: Successful Completion of Phase 1 Clinical Trial Dosing
	AGN AGN Ann: Ceasing to be a substantial holder
	AGN AGN Ann: SRC Approves Commencement Of Fourth And Final Cohort Dosing
	AGN AGN Ann: Change of Director's Interest Notice
	AGN AGN Ann: Notification regarding unquoted securities - AGN
	AGN AGN Ann: Phase 1 Clinical Trial Progress Update
	AGN AGN Ann: AGM Presentation
	AGN AGN Ann: Results of Annual General Meeting
	AGN AGN Ann: Safety Review Committee Approves Third Cohort Commencement
	AGN AGN Ann: Sentinel Subjects Dosed in Second Cohort of Phase 1 Trial
	AGN AGN Ann: Safety Review Committee Approves Second Cohort
	AGN AGN Ann: Quarterly Activities/Appendix 4C Cash Flow Report
	AGN AGN Ann: No Serious Safety Issues Observed in First Cohort
	AGN AGN Ann: Notice of Annual General Meeting/Proxy Form
	AGN AGN Ann: Investor Presentation
	AGN AGN Ann: First Healthy Adult Subject Dosed in Phase 1 Trial of ARG007
	AGN AGN Ann: Argenica Receives $1.38m R&D Tax Incentive Cash Refund
	AGN AGN Ann: Further Positive Preclinical Results for ARG-007 In HIE
	AGN AGN Ann: Date of AGM and Closing Date for Director Nominations
	AGN AGN Ann: Phase 1 Clinical Trial Summary
	AGN AGN Ann: Argenica Receives Ethics Approval To Commence Phase 1 Trial
	AGN AGN Ann: Appendix 4G & Corporate Governance Statement
	AGN AGN Ann: Appendix 4E & Annual Report 30 June 2022
	AGN AGN Ann: Ethics Application Submitted for Phase 1 Trial
	AGN AGN Ann: Quarterly Activities/Appendix 4C Cash Flow Report
	AGN AGN Ann: Clinical Advisory Committee Appointment
	AGN AGN Ann: Notification regarding unquoted securities - AGN
	AGN AGN Ann: Peer Reviewed Paper Published on Preclinical Safety Study

Register to track AGN and receive email alerts.

End of Day Prices

Date	Close	Volume	Change
18-Sep	$0.29	381,039	-0.03 (9.38%)
12-Sep	$0.32	1,380,327	-0.02 (4.48%)
11-Sep	$0.34	1,672,316	+0.09 (36.73%)
05-Sep	$0.25	1,259,832	-0.01 (2.00%)
04-Sep	$0.25	4,300,175	-0.03 (10.71%)
03-Sep	$0.28	9,955,244	-0.37 (56.59%)
29-Aug	$0.65	253,229	+0.01 (0.78%)
28-Aug	$0.64	211,549	-0.05 (6.57%)
22-Aug	$0.69	101,033	+0.01 (0.74%)
21-Aug	$0.68	86,125	-0.05 (6.85%)
15-Aug	$0.73	116,359	+0.05 (7.35%)
14-Aug	$0.68	224,518	-0.01 (0.73%)
07-Aug	$0.69	70,838	+0.01 (0.74%)
31-Jul	$0.68	90,268	0.00 (0.00%)
30-Jul	$0.68	9,527	0.00 (0.00%)
5 up, 8 down, and 2 flat days